Release no. 1/2011

Copenhagen and Oslo, 31st January, 2011, 2011-01-31 10:36 CET (GLOBE NEWSWIRE)
--Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced
that the European Patent Office (EPO) recently granted European patent (EP
1800133) covering the Company's proprietary Cell Based Antibody Selection
(CBAS(TM)) technology. The newly granted EU patent considerably strengthens
Affitech's IP position regarding its CBAS(TM) technology which is used to
generate antibodies to highly complex antigens on cell surfaces.

AT008/CCR4, an important preclinical programme in Affitech's portfolio targets
CCR4, a G-protein coupled receptor involved in the progression of cancer and
certain inflammatory conditions, and was generated using CBAS(TM) technology.

The CBAS(TM) patent has also recently been granted in Russia as patent RU
2402777and in addition is already granted in Singapore, South Africa and New
Zealand and is pending in several other countries incl. Japan and the USA.

Affitech further announced that the United States Patent and Trademark Office
(USPTO) has granted a patent on multivalent multispecific antibodies (US
7,838,637) that covers a specific format of recombinant antibody and antibody
fragments. Such formats could, for example, be used to direct and enhance the
body's immune response to specific tumors or multiple pathways. This format
enables the construction of next generation designer antibodies which allow new
approaches for the treatment of cancer and other serious diseases.

Commenting on the two new patents Managing Director of Affitech A/S Martin
Welschof said:

“The granting of the European CBAS(TM) patent is an important part of our IP
portfolio and is fundamental to our strategic focus on developing antibodies to
highly complex targets in their natural environment, such as G protein coupled
receptors. The USPO patent on multispecific antibodies provides us with an
important new format, allowing additional modes of action to tackle unmet
medical needs and is now part of our integrated antibody technology platform.”

Affitech ASis a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS™. Further information is available at
www.affitech.com.

Disclaimer
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of the financial condition and operations of Affitech A/S. There are many
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements and
forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.

No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided
herein, and no claims shall be made by the recipient of this news release by
virtue of the information contained herein.



Contact:
Randi Krogsgaard, Director IR & Corporate Communications
Tel # +45 2320 1001, e-mail: [email protected]

110131_PR_1_patents_UK.pdf